Fundraising for Biotech and Deep Tech

Fundraising for biotech and deep tech is fundamentally different from fundraising for software. Investors usually underwrite technical progress, regulatory progress, and team credibility long before they underwrite revenue. The practical rule is simple: raise against a clear de-risking milestone, not a vague promise of future traction.

That is why many biotech, medtech, climate, robotics, hardware, and other deep tech companies use a mix of grants, strategic partnerships, institutional capital, and sometimes community capital. Community rounds can be a good fit, including in the US through structures such as Reg CF, but only when the science is explained clearly and the next milestone is concrete.

Do not force a SaaS story onto a science company.

What is different about fundraising for biotech and deep tech?

The biggest difference is what counts as proof. In software, early proof is often usage, retention, and revenue. In biotech and deep tech, early proof is usually evidence that the underlying science or engineering works and that the company can get to the next meaningful milestone.

Dimension	Software startup	Biotech or deep tech startup
What investors often look for first	User growth, retention, revenue, sales efficiency	Technical feasibility, reproducibility, regulatory or manufacturing progress, commercial validation
Feedback loop	Often measured in weeks or months	Often measured in months or years
Capital profile	Can often iterate relatively cheaply	Lab work, hardware, testing, certification, or clinical work can be capital intensive
Main early risk	Will users adopt it and will it scale?	Will it work, can it be built reliably, and can it reach market in a practical way?
Value inflection points	Product and go-to-market metrics	Named technical, regulatory, manufacturing, or commercial milestones

That does not mean revenue is irrelevant. It means revenue is often late evidence, not early evidence. Before revenue becomes meaningful, investors want to see whether the company is getting materially less risky.

What are investors really underwriting?

For most biotech and deep tech companies, early investors are underwriting six things:

• Technical feasibility: does the core approach appear capable of working?
• Reproducibility: do the results hold up beyond a one-off demo?
• Development path: is there a credible plan from here to the next inflection point?
• Commercial usefulness: if the product works, will someone adopt it, buy it, or partner around it?
• Team credibility: can this team execute the science, engineering, and company-building required?
• Defensibility: is there some durable edge, such as IP, know-how, data, process, or strategic position?

The key is not to present these as abstract claims. Show the evidence that supports each one.

A good fundraising milestone removes a real reason to say no.

What should you raise against instead of revenue?

If revenue is not yet the right proof point, the real question becomes: what milestone meaningfully de-risks the company? Good milestones are specific, checkable, and tied to value creation.

• IP progress: patent filings or grants, licensing status, or freedom-to-operate work where relevant
• Scientific or engineering progress: reproducible data, benchmark performance, assay development, durability, stability, accuracy, sensitivity, or yield improvements
• Regulatory or quality progress: pre-submission meetings, IND-enabling work, protocol readiness, quality system work, or testing plans, where applicable
• Commercial signals: design partners, pilots, paid evaluations, LOIs, strategic interest, non-dilutive awards, or customer discovery that changes the product roadmap
• Manufacturing readiness: BOM cost targets, supplier qualification, scale-up progress, throughput, process consistency, or packaging and distribution readiness

A useful milestone usually has five traits:

1. It is easy to name in one sentence.
2. An outsider can understand why it matters.
3. It reduces a real technical, regulatory, or commercial risk.
4. It can be evaluated with evidence.
5. It makes the next financing or partnership conversation easier.

Rule of thumb: if an intelligent person outside your lab cannot understand why the milestone matters, it is not framed well enough for fundraising.

If this round does not buy clear de-risking, it is probably too small, too vague, or both.

How do you tell the deep tech story without dumbing it down?

The best biotech and deep tech pitches usually do four things in order: explain the problem, establish credibility, show the evidence, and define what this round unlocks.

1) Lead with the problem and who it hurts

Start with the real-world pain, not with a wall of technical detail. In biotech, that may be a specific patient population and what current care fails to do. In climate, robotics, hardware, energy, or industrial tech, it may be a cost curve, reliability problem, supply bottleneck, labor constraint, safety issue, or regulatory requirement that current solutions do not solve well enough.

Good openings answer two questions fast: why does this matter, and why is the current approach insufficient?

2) Establish credibility quickly

Investors do not need a heroic origin story. They need evidence that your team can execute.

• Relevant prior work in the field
• Clinical, scientific, or engineering experience tied to the problem
• Publications, presentations, or technical recognition where appropriate
• Advisors who actually contribute, and what they help with
• Customer or partner conversations with domain experts, even if you cannot sell yet

3) Show the evidence trail

Do not just say the company is a breakthrough. Show what has been tested, what the results suggest, and what remains uncertain.

• Prototype or experimental results, and what they prove
• What has been repeated or independently validated
• Known bottlenecks and open technical questions
• Why your approach is more promising than the alternatives you are aware of

This is where many founders lose trust. Overclaiming early data is worse than admitting what you still need to prove.

4) Be explicit about what this round funds

The ask should be concrete. Investors should be able to answer: what work will this money fund, what milestone should it achieve, and why does that milestone matter?

For example, the point is not just “we need runway.” The point is “this capital gets us to a named milestone that changes the quality of the next financing, partnership, or regulatory conversation.”

“Breakthrough” is not a fundraising argument. Evidence is.

When do community rounds make sense for biotech and deep tech?

By “community round,” I mean a fundraising process that lets a broader group of supporters participate than a traditional angel or VC round. In the US, that can include exemptions such as Reg CF, but the exact structure, disclosures, investor limits, and process depend on the offering and jurisdiction.

Community rounds can work well in biotech and deep tech because these companies often have real communities before they have revenue. Those communities may include patients, caregivers, researchers, engineers, practitioners, climate advocates, industry insiders, or customers who want the product to exist.

Why community rounds can work

• You are not forced to pretend early revenue is the main proof of value.
• You can raise from supporters who understand why the problem matters.
• A well-run round can complement grants, strategic partnerships, and institutional capital.
• It can help fund a specific milestone that makes later institutional fundraising easier.

The best use case is usually focused and practical: raise enough to hit a meaningful milestone, then come back to institutional investors with less technical risk.

When a community round is a poor fit

• Your story only makes sense to a tiny group of specialists and cannot be explained clearly in public-facing materials.
• You do not have a real community, only the hope that one will appear during the raise.
• The round is so small that the legal, platform, and operational work may not be worth it.
• You are not ready for the disclosure and investor communication burden that comes with a broader base of investors.
• You are trying to use community enthusiasm to paper over weak evidence.

Community rounds are not a shortcut around diligence. They still require clear risk disclosure, disciplined communication, and careful handling of scientific and forward-looking claims.

Community enthusiasm does not fix weak science.

How should biotech and deep tech companies combine funding sources?

Most deep tech companies do not rely on one source of capital. They use a stack. The right question is not “which source is best?” It is “which source is best for this milestone?”

Funding source	Often best for	Main tradeoff
Non-dilutive funding	Early R&D, feasibility work, and technical validation	Application cycles can be slow, and the funding may come with program constraints
Strategic partnerships	Pilots, validation, distribution insight, or development support	Partner processes can be slow, and deal terms can affect future flexibility
Institutional capital	Larger rounds, company-building, and financing major inflection points	High diligence burden and a high bar on evidence and future financing logic
Community rounds	Mission-aligned supporters, bridge capital, and broader participation around a clear milestone	Public-facing disclosure, compliance, and ongoing investor communication add work

Used well, these sources can reinforce each other. A grant can validate the science, a strategic can validate commercial interest, a community round can fund the next proof point, and institutional investors can finance the next major scale-up. Used badly, they create distraction and mismatched expectations.

If you are fundraising for a therapeutics biotech, what stages do investors usually recognize?

This is a simplified map, and it is most applicable to therapeutics. Medtech, diagnostics, tools, and platform companies follow different paths. Costs, timelines, and evidence standards also vary by modality, indication, study design, geography, and counsel.

Stage	What you are proving	Example milestone investors often recognize
Discovery	There is a defensible target, mechanism, or approach worth pursuing	Lead or target identification supported by compelling early data
Preclinical	The program works in relevant models and can be developed with reasonable rigor	Meaningful progress toward an IND-enabling package or equivalent preclinical package
First-in-human	The product appears safe enough to study in humans and behaves as expected	Early safety, tolerability, and PK or PD readouts where applicable
Proof-of-concept	There is a meaningful efficacy or utility signal in the intended population	Clinical signal on a defined endpoint
Pivotal or late-stage	The product can meet the bar for approval and commercialization	Pivotal trial readout or equivalent late-stage evidence

If you publish capital ranges for these stages, review them carefully. “Typical cost” varies so much by program that loose numbers can mislead investors and reduce credibility.

What mistakes do biotech and deep tech founders make when fundraising?

• Acting as if they need SaaS-style traction before they are allowed to raise.
• Confusing activity with de-risking. Running many experiments is not the same as hitting a milestone investors care about.
• Overstating what early data proves.
• Hiding the hardest risks instead of naming them and showing the plan to address them.
• Raising an amount that does not actually get the company to the next meaningful inflection point.
• Using jargon that obscures the problem, the proof, or the ask.
• Treating community investors like donors instead of investors who deserve clear communication.
• Setting terms without thinking about how the next round will work.

The common thread is the same: founders lose credibility when the story is less precise than the work.

Frequently asked questions

Can a pre-revenue biotech or deep tech company raise money?

Often, yes. Pre-revenue is normal in these categories. What matters is whether you can explain the risks clearly and show concrete progress toward a milestone that creates value.

How should I think about valuation for deep tech?

Valuation usually depends on stage, quality of evidence, IP position, market potential, team quality, and comparable financings at similar milestones. In practice, founders often sanity-check terms against recent deals in their category and then ask whether the structure leaves room for future rounds. Because valuation is highly company-specific, it is worth pressure-testing with counsel and investors who know the sector.

Where do biotech and deep tech founders actually find investors?

• Patient, caregiver, and disease-focused communities for relevant biotech and medtech companies
• University, lab, and alumni networks
• Industry-specific associations, forums, and practitioner communities
• Conferences where technical buyers, partners, and researchers gather
• Strategic partners, design partners, and customers who already understand the pain point

The best channel is usually the one where people already understand why the problem matters.

How much technical detail should I share if IP is sensitive?

Share enough for an investor to understand the mechanism, the evidence, and why the result matters. Do not disclose trade secrets casually in public materials. The right level of detail depends on your IP strategy, the audience, and the fundraising channel, so coordinate with counsel where the stakes are high.

Can a community round replace institutional capital?

Usually not on its own. For many biotech and deep tech companies, community capital works best as a complement or bridge, not a permanent substitute for grants, strategics, angels, or venture investors. The right mix depends on the stage, the amount needed, and how specialized the diligence is likely to be.

Bottom line

Biotech and deep tech companies do not win by pretending they are software companies. They win by being specific about what they are proving, why their team can prove it, and what the next milestone unlocks. If the story is clear, the evidence is real, and the round is sized to reach a meaningful inflection point, early fundraising is possible even without near-term revenue.